CLARIVATE PLC 8-K

What Happened
Clarivate PLC announced on July 3, 2026 that certain subsidiaries entered into a Stock and Asset Purchase Agreement to sell its Life Sciences & Healthcare business to an affiliate of Altaris, LLC. The agreed aggregate purchase price is $600,000,000, and the transaction is expected to close by the end of calendar year 2026, subject to regulatory approvals and customary closing conditions. Clarivate does not need shareholder approval for the sale.

Key Details

• Total purchase price: $600,000,000 composed of $500,000,000 cash at closing (subject to customary closing adjustments), $25,000,000 deferred consideration (payable no later than Jan 31, 2028), and a $75,000,000 unsecured senior note issued by a Buyer affiliate to a Clarivate subsidiary at closing.
• Closing conditions include regulatory approvals, accuracy of reps & warranties, and customary covenants; Clarivate must operate the business in the ordinary course before closing (with certain exceptions).
• Buyer financing: Buyer has obtained equity and debt financing commitments; Altaris-affiliated funds committed equity and have provided a limited guarantee (including guaranteeing a $33,000,000 termination fee in certain circumstances).
• Executive retention: On July 3, 2026 Clarivate entered a retention agreement with Henry Levy, President, Life Sciences & Healthcare — unvested RSUs will vest if the deal closes before March 31, 2027 (subject to continued employment); performance share units will be canceled at closing; certain severance protections apply if Mr. Levy is terminated without cause within six months post-closing.

Why It Matters
This is a significant divestiture of Clarivate’s Life Sciences & Healthcare segment for $600M in combined cash, deferred pay and a note, and could reshape the company’s business mix and use of proceeds (subject to management decisions). The deal is conditional on regulatory approval and customary closing steps, so timing and final terms could change. The retention and severance arrangements for the business leader indicate an effort to protect continuity through the transition.